Bedford, MA
Summary
This biopharmaceutical company focuses on developing and commercializing innovative therapies for retinal diseases and other eye conditions. Their product offerings include sustained-release implants and biodegradable alternatives to traditional treatments, aiming to improve patient outcomes in ophthalmology. The company is engaged in clinical trials and has a pipeline that includes products for conditions such as wet age-related macular degeneration and glaucoma.
Based on content on ocutx.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
15.0 years — Since Jan 2010
Web Hosting
Platform
E-Mail Provider
Mimecast
NAICS Code
325412
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Biopharmaceuticals specializing in ophthalmic treatments.
2. Pharmaceutical Preparation Manufacturing
Vendor
Source
Microsoft
TXT Record
Apple
TXT Record
DocuSign
TXT Record
TXT Record
Smartsheet
TXT Record
Salesforce
TXT Record
Mimecast
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|